MiraLAX (Polyethylene Glycol 3350) for Constipation
MiraLAX (polyethylene glycol 3350) should be dosed at 17 grams once daily, mixed in 8 ounces of liquid, and is strongly recommended as a first-line osmotic laxative for chronic constipation with proven efficacy and safety for up to 6 months of continuous use. 1
Recommended Dosing and Administration
Standard Dose
- Initial dose: 17 g once daily 1
- Administration: Mix powder in 8 ounces (approximately 240 mL) of any beverage 1
- Timing: Once daily dosing; no specific time of day required
- Titration: Adjust dose based on symptom response and side effects 1
- Maximum dose: No clear maximum dose established, though titration upward may be needed in some patients 1
Duration of Use
The 2023 AGA-ACG guidelines provide a strong recommendation for PEG use based on moderate-quality evidence showing durable response over 6 months 1. While FDA-approved for "occasional constipation," clinical trials demonstrate sustained efficacy in chronic idiopathic constipation for at least 24 weeks 1, 2.
Mechanism of Action
PEG 3350 functions as an osmotic laxative—a long-chain polymer of ethylene oxide that traps water in the intestinal lumen, softening stool and increasing stool bulk without being absorbed systemically 1.
Clinical Efficacy
The evidence supporting PEG is robust:
- Increases complete spontaneous bowel movements (CSBMs): Mean difference of 2.90 per week vs. placebo 1
- Increases spontaneous bowel movements (SBMs): Mean difference of 2.30 per week vs. placebo 1
- Responder rate: 3.13 times higher than placebo (312 more responders per 1,000 patients) 1
- Global symptom relief: 454 per 1,000 patients achieved relief vs. placebo 1
- FDA endpoint achievement: 42% vs. 13% with placebo over 24 weeks 2
PEG demonstrates superior or equivalent efficacy compared to lactulose, tegaserod, and prucalopride in head-to-head trials 1.
Common Side Effects
Expected gastrointestinal effects (consistent with osmotic laxative mechanism) 1:
- Bloating and abdominal distension
- Flatulence
- Abdominal discomfort/cramping
- Diarrhea (158 more per 1,000 vs. placebo)
- Nausea
Important clinical note: Most adverse events are mild to moderate and decrease markedly after the first week of treatment 2. Serious adverse events are rare, with no conclusive evidence of increased risk (RR 0.47, CI 0.16–1.33) 1.
Contraindications and Precautions
While the provided evidence does not explicitly list contraindications from FDA labeling, clinical considerations include:
- Bowel obstruction or perforation: Avoid in suspected mechanical obstruction
- Adequate hydration: Ensure patients maintain fluid intake, particularly when combining with fiber supplementation 1
- Pregnancy: PEG has been studied, though lactulose is noted as the only osmotic agent specifically studied in pregnancy 1
Clinical Algorithm for Use
Step 1: Consider PEG 3350 as first-line therapy for chronic constipation, either after a trial of fiber supplementation or in combination with fiber 1
Step 2: Initiate at 17 g once daily mixed in 8 ounces of liquid 1
Step 3: Assess response after 1 week (most GI side effects diminish after first week) 2
Step 4: Titrate dose based on:
- Stool frequency and consistency
- Symptom relief (straining, hardness, incomplete evacuation)
- Tolerability of side effects 1
Step 5: Continue for sustained benefit—efficacy proven durable through 6 months 1
Key Clinical Advantages
- Cost-effective: $10-45 per month 1
- Over-the-counter availability: No prescription required 1
- Grit-free, unflavored powder: High patient acceptability 3
- Once-daily dosing: Improves adherence 4
- Long-term safety profile: Well-tolerated for extended use 1, 5
Common Pitfalls to Avoid
Premature discontinuation: Many patients experience initial bloating/gas that resolves after the first week—counsel patients to continue through this adjustment period 2
Inadequate fluid intake: Ensure patients understand the importance of mixing with adequate liquid and maintaining hydration 1
Expecting immediate results: While some improvement occurs within days, optimal benefit may take 1-2 weeks 6
Limiting to "occasional" use only: Despite FDA labeling for occasional constipation, strong evidence supports chronic use for up to 6 months in chronic idiopathic constipation 1